Dengue Vaccine Candidate

Takeda’s Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years in Pivotal Clinical Tria

Jun 10, 2022

Takeda today announced that its dengue vaccine candidate, TAK-003, prevented 84% of hospitalized dengue cases and 61% of symptomatic cases, with no important safety risks identified, in the overall...

Videos

What Are The Main Challenges In India’s Real Estate Sector? | NAR India 2019

August 30, 2019

You are here

Dengue Vaccine Candidate

Takeda’s Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years in Pivotal Clinical Tria

October 5 to October 8: Andhra Pradesh to Witness Non-Stop Rains for Next 3 Days

What Are The Main Challenges In India’s Real Estate Sector? | NAR India 2019

What Are The Main Challenges In India’s Real Estate Sector? | NAR India 2019